Suppr超能文献

一种用于肿瘤中总抗体摄取的机制房室模型。

A mechanistic compartmental model for total antibody uptake in tumors.

机构信息

Dept. Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

出版信息

J Theor Biol. 2012 Dec 7;314:57-68. doi: 10.1016/j.jtbi.2012.08.034. Epub 2012 Sep 6.

Abstract

Antibodies are under development to treat a variety of cancers, such as lymphomas, colon, and breast cancer. A major limitation to greater efficacy for this class of drugs is poor distribution in vivo. Localization of antibodies occurs slowly, often in insufficient therapeutic amounts, and distributes heterogeneously throughout the tumor. While the microdistribution around individual vessels is important for many therapies, the total amount of antibody localized in the tumor is paramount for many applications such as imaging, determining the therapeutic index with antibody drug conjugates, and dosing in radioimmunotherapy. With imaging and pretargeted therapeutic strategies, the time course of uptake is critical in determining when to take an image or deliver a secondary reagent. We present here a simple mechanistic model of antibody uptake and retention that captures the major rates that determine the time course of antibody concentration within a tumor including dose, affinity, plasma clearance, target expression, internalization, permeability, and vascularization. Since many of the parameters are known or can be estimated in vitro, this model can approximate the time course of antibody concentration in tumors to aid in experimental design, data interpretation, and strategies to improve localization.

摘要

正在开发针对多种癌症(如淋巴瘤、结肠癌和乳腺癌)的抗体治疗方法。这类药物的疗效受到限制,主要是因为其在体内的分布不佳。抗体的定位速度较慢,往往达不到足够的治疗剂量,并且在肿瘤内分布不均匀。虽然单个血管周围的微分布对于许多治疗方法很重要,但对于许多应用(如成像、用抗体药物偶联物确定治疗指数以及放射免疫治疗中的剂量),抗体在肿瘤中的总定位量至关重要。对于成像和预靶向治疗策略,摄取的时间过程对于确定何时进行图像采集或输送二次试剂至关重要。我们在这里提出了一种简单的抗体摄取和保留的机制模型,该模型捕获了决定肿瘤内抗体浓度时间过程的主要速率,包括剂量、亲和力、血浆清除率、靶表达、内化、通透性和血管化。由于许多参数是已知的或可以在体外估计,因此该模型可以近似抗体在肿瘤中的浓度时间过程,以帮助实验设计、数据解释和改善定位的策略。

相似文献

6
CD70 as a therapeutic target in human malignancies.CD70作为人类恶性肿瘤的治疗靶点。
Expert Opin Ther Targets. 2008 Mar;12(3):341-51. doi: 10.1517/14728222.12.3.341.

引用本文的文献

3
Modernizing Preclinical Drug Development: The Role of New Approach Methodologies.现代化临床前药物研发:新方法学的作用。
ACS Pharmacol Transl Sci. 2025 May 29;8(6):1513-1525. doi: 10.1021/acsptsci.5c00162. eCollection 2025 Jun 13.

本文引用的文献

1
A systems approach for tumor pharmacokinetics.肿瘤药代动力学的系统方法。
PLoS One. 2011;6(9):e24696. doi: 10.1371/journal.pone.0024696. Epub 2011 Sep 14.
2
(124)I-huA33 antibody PET of colorectal cancer.(124)I-huA33 抗体 PET 显像探测大肠癌。
J Nucl Med. 2011 Aug;52(8):1173-80. doi: 10.2967/jnumed.110.086165. Epub 2011 Jul 15.
4
Scaling rules for diffusive drug delivery in tumor and normal tissues.肿瘤和正常组织中扩散药物输送的缩放规则。
Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1799-803. doi: 10.1073/pnas.1018154108. Epub 2011 Jan 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验